-
公开(公告)号：US20120183471A1
公开(公告)日：2012-07-19
申请号：US13201061
申请日：2010-02-17
申请人： Lloyd J. Old , Constance Old , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Terrance Grant Johns , Con Panousis , Christoph Renner
发明人： Lloyd J. Old , Constance Old , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Terrance Grant Johns , Con Panousis , Christoph Renner
IPC分类号： A61K39/395 , A61P35/00 , C12N1/19 , G01N33/574 , C12N5/10 , C12N1/21 , C07K16/30 , A61K51/00
CPC分类号： C07K16/40 , A61K31/495 , A61K39/39541 , A61K39/39558 , A61K47/6871 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2300/00 , C07K16/2863 , C07K16/30 , C07K16/4258 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。
-
公开(公告)号：US20110076232A1
公开(公告)日：2011-03-31
申请号：US12890029
申请日：2010-09-24
申请人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Gerd Ritter
发明人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Gerd Ritter
IPC分类号： A61K51/10 , C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2863 , A61K39/39558 , A61K51/103 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/30 , C07K16/4266 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。
-
公开(公告)号：US20110293511A1
公开(公告)日：2011-12-01
申请号：US13078781
申请日：2011-04-01
申请人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan , Stephen Stockert
发明人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan , Stephen Stockert
IPC分类号： A61K39/395 , A61K38/21 , A61K38/20 , A61K103/20 , A61K103/40 , A61K103/30 , A61K103/32 , A61K103/00 , A61P35/00
CPC分类号： C07K16/4266 , A61K39/39558 , A61K51/103 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
-
公开(公告)号：US20110313230A1
公开(公告)日：2011-12-22
申请号：US13078764
申请日：2011-04-01
申请人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan
发明人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan
CPC分类号： A61K39/3955 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2863 , C07K16/30 , C07K16/4241 , C07K16/4258 , C07K16/4266 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/90 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译： 本发明涉及在过表达EGFR的肿瘤细胞上结合EGFR的特异性结合成员，特别是抗体及其片段，以及表达EGFR受体截短型de2-7EGF的肿瘤细胞。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。
-
公开(公告)号：US09045533B2
公开(公告)日：2015-06-02
申请号：US14037504
申请日：2013-09-26
申请人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
发明人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
IPC分类号： C12P21/08 , C12N5/10 , C07K16/18 , C07K16/28 , C07K14/705 , C07K16/30 , A61K39/395 , C07K7/08 , C07K14/47 , A61K39/00
CPC分类号： C07K16/3069 , A61K39/00 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/53 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , G01N33/57449 , G01N2333/705 , G01N2500/04
摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。
-
6.发明申请公开(公告)号：US20170362336A1
公开(公告)日：2017-12-21
申请号：US15609839
申请日：2017-05-31
申请人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
发明人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
IPC分类号： C07K16/30 , A61K39/00 , A61K39/395 , G01N33/574 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C07K7/08
CPC分类号： C07K16/3069 , A61K39/00 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/53 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , G01N33/57449 , G01N2333/705 , G01N2500/04
摘要： The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
-
7.发明申请Membrane Transporter NaPi2b (SCL34A2) Epitope for Antibody Therapy, Antibodies Directed Thereto, and Target for Cancer Therapy 有权膜转运体NaPi2b（SCL34A2）抗体治疗表位，针对其的抗体和癌症治疗靶向公开(公告)号：US20140193417A1
公开(公告)日：2014-07-10
申请号：US14037504
申请日：2013-09-26
申请人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
发明人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
IPC分类号： C07K16/18 , A61K39/00 , C07K7/08 , A61K39/395 , C07K14/47
CPC分类号： C07K16/3069 , A61K39/00 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/53 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , G01N33/57449 , G01N2333/705 , G01N2500/04
摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。
-
8.发明申请Membrane Transporter NaPi2b (SCL34A2) Epitope for Antibody Therapy, Antibodies Directed Thereto, and Target for Cancer Therapy 有权膜转运体NaPi2b（SCL34A2）抗体治疗表位，针对其的抗体和癌症治疗靶向公开(公告)号：US20160009816A1
公开(公告)日：2016-01-14
申请号：US14693261
申请日：2015-04-22
申请人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
发明人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
IPC分类号： C07K16/30 , A61K39/00 , G01N33/574 , C07K14/705
CPC分类号： C07K16/3069 , A61K39/00 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/53 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , G01N33/57449 , G01N2333/705 , G01N2500/04
摘要： The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
摘要翻译： 本发明一般涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。
-
公开(公告)号：US09072798B2
公开(公告)日：2015-07-07
申请号：US13201061
申请日：2010-02-17
申请人： Gerd Ritter , Anne Murray , George Mark , Christoph Renner
发明人： Gerd Ritter , Anne Murray , George Mark , Christoph Renner
CPC分类号： C07K16/40 , A61K31/495 , A61K39/39541 , A61K39/39558 , A61K47/6871 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2300/00 , C07K16/2863 , C07K16/30 , C07K16/4258 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。
-
10.发明申请Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy 有权用于抗体治疗的膜转运体NaPi2b（SCL34A1）表位，针对其的抗体和用于癌症治疗的靶标公开(公告)号：US20110129483A1
公开(公告)日：2011-06-02
申请号：US12735576
申请日：2009-01-29
申请人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lioyd Old , Kenneth Lioyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
发明人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lioyd Old , Kenneth Lioyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
IPC分类号： A61K39/395 , C07K16/18 , C12N15/13 , C12N1/21 , C12N1/19 , C12N5/07 , C12N5/04 , C07K14/435 , C07K7/08 , A61K39/00 , A61K38/00 , G01N33/53 , A61P35/00 , A61P37/00
CPC分类号： C07K16/3069 , A61K39/00 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/53 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , G01N33/57449 , G01N2333/705 , G01N2500/04
摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide (s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.074 秒)
